Italian pharmaceutical glass containers provider Stevanato Group and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed an agreement for the supply of Borosilicate glass vials.

As part of this agreement, Stevanato will supply 100 million Type 1 Borosilicate glass vials to hold up to two billion doses of Covid-19 vaccine.

Additionally, the group will offer ‘fast track’ access to its glass vial forming lines provided by its company Spami.

The agreement is still subject to the safe and effective development of the product.

Stevanato Group CEO Franco Stevanato said: “We are proud to support CEPI in this important project. We share the same deep sense of responsibility and commitment to achieving our industry goal of successfully addressing this public health challenge, ensuring no patient is left behind.”

The supply agreement is part of CEPI’s efforts to accelerate the development of vaccine by making progress on manufacturing and the clinical development of candidate vaccines simultaneously.

Investing up to $829m, CEPI has worked in coordination with its partners, in nine Covid-19 vaccine candidates.

CEPI CEO Dr Richard Hatchett said: “In addition to accelerating the development of Covid-19 vaccine candidates, CEPI is working with partners around the world to begin the manufacture of millions of vaccine doses so that, should a candidate be proven to be safe and effective, it will be available to those in need without delay.

“In order to achieve this aim, CEPI is supporting the procurement of critical vaccine packaging components, including glass vials. We are therefore delighted to be working with the Stevanato Group to secure high-quality pharma vials for two billion doses of vaccine, helping to maximise our efforts to advance the development of a Covid-19 vaccine and bring this pandemic to an end as soon as possible.”